<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367547</url>
  </required_header>
  <id_info>
    <org_study_id>JointAPHSHC</org_study_id>
    <secondary_id>2014-002746-50</secondary_id>
    <nct_id>NCT02367547</nct_id>
  </id_info>
  <brief_title>Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL</brief_title>
  <official_title>Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: Hexylaminolevulinate and Aminolevulinic Acid Nano Emulsion Versus Methylaminolevulinate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Authority for Päijät-Häme Social and Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Jyvaskyla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joint Authority for Päijät-Häme Social and Health Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study compares three photosensitisers, hexylaminolevulinate (HAL) and
      aminolevulinic acid nano emulsion (BF-200 ALA) to methylaminolevulinate (MAL) in photodynamic
      therapy of superficially growing basal cell carcinomas. Study is conducted using randomised
      prospective double blinded comparing design. Fluorescence is measured in A.U. (Arbitrary
      Unit) with standardised set-up before and after the exposure. Efficacy is assessed
      clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study recruits volunteering patients, who are referred to the department of dermatology and
      allergology, Päijät-Häme Central Hospital, Lahti, with 99 clinically assessed superficial
      basal cell carcinoma on the body area, not face and scalp. Diagnoses is confirmed
      histologically by punch biopsies and hyperspectral images are taken before the biopsies. The
      lesions are randomised in three groups: interventions HAL and BF-200 ALA and comparator MAL.
      Photodynamic therapy is given by the standard procedure. Fluorescence is measured in A.U.
      (Arbitrary Unit) with standardised set-up, with Wood's light, digital camera and a yellow
      lens, before and after the exposure. Pain is measured in VAS-scale before, during and after
      the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging
      system at 3 months, 12 months and 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological lesion clearance</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological lesion clearance</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological lesion clearance</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of subclinical lesion with hyperspectral imaging system</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of subclinical lesion with hyperspectral imaging system</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of subclinical lesion with hyperspectral imaging system</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Fluorescence measured in A.U. (Arbitrary Units) with standardised set-up, with Wood's light, digital camera and a yellow lens</measure>
    <time_frame>before (point 0 min) and after (point 8 min) the exposure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pain in VAS-scale</measure>
    <time_frame>in the beginning (point 0 min), middle (point 4 min) and end (point 8 min) of the exposure</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Neoplasms, Basal Cell</condition>
  <condition>Carcinoma, Basal Cell</condition>
  <condition>Photochemotherapy</condition>
  <condition>Photosensitizing Agents</condition>
  <arm_group>
    <arm_group_label>Hexylaminolevulinate cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminolevulinic Acid Nano Emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>78 mg/g Aminolevulinic Acid Nano Emulsion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylaminolevulinate cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 mg/g Methylaminolevulinate cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hexylaminolevulinate cream</intervention_name>
    <description>The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.</description>
    <arm_group_label>Hexylaminolevulinate cream</arm_group_label>
    <other_name>HAL</other_name>
    <other_name>Hexvix, Photocure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminolevulinic Acid Nano Emulsion</intervention_name>
    <description>In the study we use Ameluz.</description>
    <arm_group_label>Aminolevulinic Acid Nano Emulsion</arm_group_label>
    <other_name>Ameluz, Biofrontera</other_name>
    <other_name>L01XD04</other_name>
    <other_name>BF-200 ALA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylaminolevulinate cream</intervention_name>
    <description>In the study we use Metvix.</description>
    <arm_group_label>Methylaminolevulinate cream</arm_group_label>
    <other_name>Metvix, Galderma</other_name>
    <other_name>L01X D03</other_name>
    <other_name>MAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  superficial basal cell carcinomas on body area

          -  lesions accepted needs to be 10 cm apart from each other

        Exclusion Criteria:

          -  pigmented, morpheaform, infiltrative or nodular basal cell carcinomas

          -  lesions that are in face and scalp area

          -  pregnancy

          -  breast feeding

          -  allergy to photosensitizer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mari Grönroos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Päijänne Tavastia Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mari K Salmivuori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Päijänne Tavastia Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mari K Salmivuori, MD</last_name>
    <phone>+358505355616</phone>
    <email>salmivuori.mari.k@student.uta.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joint Authority for Päijät-Häme Social and Health Care</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Neoplasms, Basal Cell</mesh_term>
    <mesh_term>Dermatitis, Phototoxic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

